Received Feb 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | UNK | DJ22N | SC |
administered a dose of FluLaval via subcutaneous route instead of intramuscular; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a 15-month-old male patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (batch number DJ22N, expiry date 13-JUN-2025) for prophylaxis. On 22-JAN-2025, the patient received FluLaval 2024-2025 season (subcutaneous). On 22-JAN-2025, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced intramuscular formulation administered by other route (Verbatim: administered a dose of FluLaval via subcutaneous route instead of intramuscular). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 22-JAN-2025 Medical assistant reported a patient was administered a dose of FluLaval via subcutaneous route instead of intramuscular on the day of reporting, which led to an intramuscular formulation administered by other route. At the time of reporting, a repeat dose had not been administered. The vaccine administration facility was the same as primary reporter.